Stocks · News reference
Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in Australia through 2040, expanding the Company's growing global IP estateContinues expansion of global intellectual
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 14.29 percent decrease over losses of $(0.07) per share
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that IP Australia has issued a Notice of